EFFECT OF ONCE VS TWICE DAILY ADMINISTRATION OF CORTICOSTEROIDS ON BLOOD GLUCOSE IN PATIENTS WITH ANCA-VASCULITIS MEASURED BY CONTINUOUS BLOOD GLUCOSE MONITORING - A PILOT STUDY
Key facts
- Where
- Graz, AusztriaSee the site
- Phase
- 4. fázis
Where in Ausztria
- Medical University of GrazGraz, AusztriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University Of Graz
- Trial code
- EU 2024-516141-39-00
- Record updated
- 2024. november 18.
- Original description
Evaluation of whether splitting the cortisone dose to a twice daily dose leads to increased time in the glucose target range.Read full original descriptionShow less
Evaluation of whether splitting the cortisone dose to a twice daily dose leads to increased time in the glucose target range.
Inclusion: Written agreement to participate in the study after detailed explanation of the study; Male or female patients; New diagnosis of ANCA-associated vasculitis or a relapse of a known ANCA vasculitis; Age: ≥18-80 years at the time of biopsy; Aprednislon dose of 1mg/kg body weight at the time of inclusion; Wants to wear a CGM system for the duration of the study and to receive insulin therapy as needed.
Exclusion: Known diabetes mellitus; Relevant acute or chronic disease that, in the investigator's estimation, could affect the patient's safety or affect the study results; Skin changes or concomitant circumstances that prevent the placement of a glucose sensor in the examiner's assessment (e.g. scar tissue); Women capable of giving birth who are pregnant, breastfeeding, wish to become pregnant or do not use adequate contraception; Current participation in another clinical trial that would affect study results; Patient's inability to follow study procedures as required; Inability of the patient to understand the consent form.